LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aandelen Lijst・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

7.63 -0.91

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.63

Max

7.82

Belangrijke statistieken
By Trading Economics
Inkomsten	7.8M 13M
Verkoop	-4M 159M
Winstmarge	8.092
Werknemers	580
EBITDA	3.7M 32M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+150.26% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-38M 1.5B
Vorige openingsprijs	8.54
Vorige sluitingsprijs	7.63

Nieuwssentiment

By Acuity

60%

40%

316 / 374 Rangschikking in Healthcare

BioCryst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 dec 2025, 23:48 UTC

Belangrijke Marktbewegers

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8 dec 2025, 23:44 UTC

Marktinformatie

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8 dec 2025, 23:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 dec 2025, 23:13 UTC

Marktinformatie

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8 dec 2025, 23:09 UTC

Acquisities, Fusies, Overnames

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8 dec 2025, 22:46 UTC

Marktinformatie

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8 dec 2025, 22:01 UTC

Marktinformatie

Miners Poised to Do Well in 2026 -- Market Talk

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8 dec 2025, 21:51 UTC

Marktinformatie

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8 dec 2025, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

8 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

8 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 dec 2025, 21:38 UTC

Acquisities, Fusies, Overnames

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8 dec 2025, 21:38 UTC

Acquisities, Fusies, Overnames

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8 dec 2025, 21:36 UTC

Marktinformatie

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8 dec 2025, 21:12 UTC

Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 dec 2025, 21:08 UTC

Marktinformatie

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8 dec 2025, 20:38 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8 dec 2025, 20:26 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 dec 2025, 20:18 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8 dec 2025, 20:07 UTC

Marktinformatie

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8 dec 2025, 20:06 UTC

Marktinformatie

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8 dec 2025, 20:05 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 dec 2025, 20:05 UTC

Marktinformatie

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8 dec 2025, 20:01 UTC

Marktinformatie

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Peer Vergelijking

Prijswijziging

BioCryst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

150.26% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.27 USD 150.26%

Hoogste 30 USD

Laagste 8 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioCryst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan BioCryst Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

316 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.